⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CGON News
CG Oncology, Inc. Common stock
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
globenewswire.com
CGON
CG Oncology Announces New Board Member and Board Transition
globenewswire.com
CGON
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
globenewswire.com
CGON
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
globenewswire.com
CGON
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
prnewswire.com
ONCY
HCM
CGON
CCCC
IDYA
ONCY
HCM
CGON
CCCC
IDYA